Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) shares traded down 5.6% during mid-day trading on Tuesday . The company traded as low as $1.33 and last traded at $1.34. 1,900,410 shares changed hands during trading, a decline of 62% from the average session volume of 4,968,297 shares. The stock had previously closed at $1.42.
Tevogen Bio Stock Up 2.2 %
The stock's fifty day moving average price is $1.25 and its 200 day moving average price is $0.89.
Insider Activity at Tevogen Bio
In other Tevogen Bio news, insider Neal Flomenberg sold 1,078,600 shares of the firm's stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $1.62, for a total transaction of $1,747,332.00. Following the transaction, the insider now directly owns 4,254,302 shares in the company, valued at $6,891,969.24. This trade represents a 20.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 56.60% of the stock is owned by company insiders.
Hedge Funds Weigh In On Tevogen Bio
An institutional investor recently bought a new position in Tevogen Bio stock. HGC Investment Management Inc. acquired a new position in Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 223,077 shares of the company's stock, valued at approximately $82,000. HGC Investment Management Inc. owned 0.13% of Tevogen Bio at the end of the most recent reporting period.
Tevogen Bio Company Profile
(
Get Free Report)
Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
Featured Stories
Before you consider Tevogen Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tevogen Bio wasn't on the list.
While Tevogen Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
